New oral drug MRX-2843 tested in Hard-to-Treat leukemias
NCT ID NCT04872478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 50 participants will take MRX-2843 capsules daily in 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MRX-2843 (oral capsules)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat leukemias that have come back or not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 50 participants, so it is primarily checking safety and dosing, not yet proving effectiveness. The drug may cause side effects or not work at all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University - WINSHIP Cancer Center
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Emory University, Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact